Andrew has a degree in Natural Sciences from Cambridge University, UK,
specialising in genetics, with additional studies in molecular cell
biology, biochemistry, chemistry, biology of cells, crystalline materials
and mathematics. He was subsequently awarded a DPhil by the University of
Oxford for his research on the regulation of globin gene expression carried
out at the Institute of Molecular Medicine, Oxford, UK. He qualified as a
European Patent Attorney and Chartered Patent Attorney in 2005.
Andrew has experience of worldwide patent filing and prosecution on behalf
of a wide range of clients, ranging from small academic and commercial
clients to multi-national pharmaceutical companies.
Andrew's practice has principally been before the European Patent Office
and the UK Patent Office, but he also experience of worldwide patent
prosecution including in the US, Australia, China, Japan and other
territories. His work has principally been in the field of biotechnology
(including genetics, molecular biology and cell biology) and has also
covered a range of chemical and mechanical cases.
Representative technologies within Andrew's experience include: protein-
and DNA-based vaccines; novel DNA and protein molecules and associated
therapeutic applications; therapeutic antibodies; stem cell technologies;
transgenic animals and cloning methods in mammalian and avian species;
tissue culture media and supplements; microbiological assays;
microbiological cloning reagents and methods; medical devices;
sterilisation and processing of pharmaceuticals; and a variety of simple
Andrew is also involved in contentious work in Europe and the UK. In recent
years, Andrew has represented several major clients in Opposition and
Appeal proceedings before the European Patent Office including in
Opposition proceedings in respect of CRISPR/Cas9 genome editing technology.
CPA, EPA - SENIOR ASSOCIATE
CPA, EPA - ATTORNEY
CPA, EPA, RTMA ATTORNEY
CPA, EPA, RTMA - ATTORNEY
CPA, EPA – ATTORNEY
FIPAA - ATTORNEY